Putting GBM in Check

A new target added to the mix of glioblastoma CAR T antigens, MCSP, checks all of the boxes of a good cell therapy for solid tumors, according to a study in Science Translational Medicine.

Identifying solid tumor antigens for CAR T therapies has been particularly difficult because the antigens are often expressed at low levels in healthy tissues, leading to CAR T cell-induced tissue damage. In addition, other antigens are not expressed by all cells within the tumor, which can lead to incomplete tumor eradication and relapse...